Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sean Wharton, Lilian Raiber, Kristin J Serodio, Jasmine Lee & Rebecca AG Christensen. (2018) Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 11, pages 427-438.
Read now
Read now
Joel M. Neutel. (2011) A Comparison of the Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination Therapy with Irbesartan Monotherapy in the Treatment of Moderate or Severe Hypertension in Diabetic and Obese Hypertensive Patients: A Post-Hoc Analysis Review. Postgraduate Medicine 123:4, pages 126-134.
Read now
Read now
G. Bönner, W. Smolka, C. Jung & K. Bestehorn. (2009) Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: obser-vational, prospective study in primary care. Current Medical Research and Opinion 25:4, pages 981-990.
Read now
Read now
André C Schmidt, Peter Bramlage, Roger Limberg & Reinhold Kreutz. (2008) Quality of life in hypertension management using olmesartan in primary care. Expert Opinion on Pharmacotherapy 9:10, pages 1641-1653.
Read now
Read now
Articles from other publishers (24)
Pei-Ying Pai, James K. S. Wong, Zhen-Yang Cui, Yi-Yuan Lin & Shin-Da Lee. (2022) Angiotensin II Receptor Blocker Irbesartan Enhanced SIRT1 longevity Signaling Replaces the Mitochondrial Biogenetic Survival Pathway to Attenuate Hypertension-Induced Heart Apoptosis. Journal of Cardiovascular Development and Disease 9:8, pages 266.
Crossref
Crossref
David Spirk, Sarah Noll, Michel Burnier, Stefano Rimoldi, Georg Noll & Isabella Sudano. (2020) First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH). Frontiers in Cardiovascular Medicine 7.
Crossref
Crossref
S R Gilyarevsky. (2014) The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience. Systemic Hypertension 11:2, pages 67-71.
Crossref
Crossref
Assen Goudev. (2014) New Insights into the Management of Hypertension and Cardiovascular
Risk with Angiotensin Receptor Blockers: Observational Studies Help Us?. The Open Cardiovascular Medicine Journal 8:1, pages 35-42.
Crossref
Crossref
Yoichi Oikawa, Akira Shimada & Mizumi Kyo. (2013) Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan. Open Journal of Endocrine and Metabolic Diseases 03:05, pages 252-258.
Crossref
Crossref
Robert Petrella & Paul Michailidis. (2011) Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management. Clinical Therapeutics 33:9, pages 1190-1203.
Crossref
Crossref
Tatsuo Kobayashi, Yuko Akiyama, Nobuteru Akiyama, Hideaki Katoh, Sachiko Yamamoto, Kenzo Funatsuki, Toru Yanagimoto, Mitsuru Notoya, Kenji Asakura, Toshihiro Shinosaki & Kohji Hanasaki. (2010) Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells. European Journal of Pharmacology 649:1-3, pages 23-28.
Crossref
Crossref
Stanley S. Franklin & Joel M. Neutel. (2010) Efficacy and Safety of Irbesartan/HCTZ in Severe Hypertension According to Cardiometabolic Factors. The Journal of Clinical Hypertension.
Crossref
Crossref
Kevin Niswender. (2010) Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay. Diabetes, Obesity and Metabolism 12:4, pages 267-287.
Crossref
Crossref
Pablo Lapuerta & Stanley Franklin. (2009) The Risks and Benefits of Initial Irbesartan/Hydrochlorothiazide Combination Therapy in Patients With Severe Hypertension. The Journal of Clinical Hypertension 11:5, pages 277-283.
Crossref
Crossref
Peter Bramlage, Eleonore Schönrock & Peter Odoj. (2008) Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovascular Disorders 8:1.
Crossref
Crossref
G. Derosa, E. Fogari, A. D'Angelo, A. F. G. Cicero, S. A. T. Salvadeo, P. D. Ragonesi, I. Ferrari, A. Gravina, R. Fassi & R. Fogari. (2007) Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics 32:3, pages 261-268.
Crossref
Crossref
Jörg-Peter Voigt, Peter Bramlage & Heidrun Fink. (2007) Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. European Journal of Pharmacology 564:1-3, pages 131-137.
Crossref
Crossref
David H G Smith. (2007) Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage. American Journal of Cardiovascular Drugs 7:6, pages 413-422.
Crossref
Crossref
Christoph Schindler, Peter Bramlage, Martin Thoenes, Carsten Bramlage & Wilhelm Kirch. (2007) Cardiovascular Risk in Obese Hypertensive Patients Taking Various??Antihypertensive Drugs. Clinical Drug Investigation 27:10, pages 707-717.
Crossref
Crossref
J. Honorato, F. de Álvaro, C. Calvo, L. Grigorian-Shamagian, I. Parrondo, M.Á. Sánchez-Zamorano & C. Filozof. (2006) Impacto del tratamiento con irbesartán sobre la reducción del riesgo cardiovascular de pacientes hipertensos en España. Estudio KORAL-HTA. Hipertensión 23:7, pages 207-215.
Crossref
Crossref
Harrihar A. Pershadsingh. (2006) New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. Drug Development Research 67:8, pages 687-697.
Crossref
Crossref
Talma Rosenthal & Irene Gavras. (2006) Fixed-Drug Combinations as First-Line Treatment for Hypertension. Progress in Cardiovascular Diseases 48:6, pages 416-425.
Crossref
Crossref
Harrihar A. Pershadsingh. (2006) Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. The International Journal of Biochemistry & Cell Biology 38:5-6, pages 766-781.
Crossref
Crossref
Giuseppe DEROSA, Arrigo F. G. CICERO, Angela D'ANGELO, Pietro D. RAGONESI, Leonardina CICCARELLI, Mario N. PICCINNI, Fabio PRICOLO, Sibilla A. T. SALVADEO, Ilaria FERRARI, Alessia GRAVINA & Roberto FOGARI. (2006) Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-.ALPHA.. Hypertension Research 29:11, pages 849-856.
Crossref
Crossref
J. Honoratoa, F. de ?lvaro, C. Calvo, L. Grigorian-Shamagian, I. Parrondod, M.? S?nchez-Zamorano & C. Filozof. (2006) Impacto del tratamiento con irbesart?n sobre la reducci?n del riesgo cardiovascular de pacientes hipertensos en Espa?a. Estudio KORAL-HTA. Hipertensi?n y Riesgo Vascular 23:7, pages 207-215.
Crossref
Crossref
R. Sternitzky. (2005) Risikoadaptierte Therapie von Gefäßerkrankungen—Risk adapted therapy in vascular diseases: Antihypertensive treatment in peripheral arterial disease. Zeitschrift für Kardiologie 94:S4, pages iv19-iv23.
Crossref
Crossref
Kasper Rossing, Katrine J. Schjoedt, Berit R. Jensen, Frans Boomsma & Hans-Henrik Parving. (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney International 68:3, pages 1190-1198.
Crossref
Crossref
Arya M Sharma, Peter Bramlage & Wilhelm Kirch. (2005) Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity-Associated Hypertension. Clinical Drug Investigation 25:12, pages 765-776.
Crossref
Crossref